(Fraunhofer ITEM)

AGENDA



09:00 - 09:30	Registration	13:30 - 13:45	Creating therapeutic maps through deep phenotyping and multi-omics approaches I
09:30 - 09:45	Welcome I Prof. Gerd Geißlinger (Spokesman Fraunhofer CIMD)		Dr. Eduard Resch (Fraunhofer ITMP)
09:45 - 10:45 09:45 - 10:15	Clinical Research & Data Sovereignty Strengths and shortcomings of clinical research in Germany and how to overcome them I Dr. Thorsten Ruppert (vfa)	13:45 - 14:35 13:45 - 14:15	Digital Medicine Part I Better healthcare through smart technology: Digital healthcare apps - development, regulations, AI, and data protection I <i>Prof. Karl Broich (BfArM)</i>
10:15 - 10:45	Harnessing medical data - the balancing act between medical benefits and data protection I <i>Prof. Frank Ückert</i>	14:15 - 14:35	(Federated) data networks for scientific collaborations I <i>Dr. Tine Lewi (Janssen)</i>
	(Universitätsklinikum Hamburg-Eppendorf)	14:35 - 15:35	Poster Presentation & Coffee Break
10:45 - 11:30 10:45 - 11:00	Fraunhofer CIMD: Research Insights Part I RNA-therapeutics for immune-mediated diseases Prof. Thomas Thum (Fraunhofer ITEM and MHH)	15:35 - 15:55 15:35 - 15:55	Digital Medicine Part II German initiatives for digital medicine: From GAIA-X to NfDIs I <i>Prof. Horst Hahn</i> (Fraunhofer MEVIS)
11:00 - 11:15 11:15 - 11:30	Cell therapeutics for immune-mediated diseases <i>Prof. Ulrike Köhl (Fraunhofer IZI)</i> New treatment strategies for immune-	15:55 - 16:55 15:55 - 16:15	Perspectives in Immunology Novel drug classes and perspectives for immune-mediated diseases I <i>Dr. Thomas</i> Hanke (Evotec)
	mediated diseases: Tolerogenic protein complexes and aptamers <i>Prof. Harald Burkhardt (University Hospital Frankfurt/Main)</i>	16:15 - 16:35	Chronic inflammatory bowel disease: Medical need and perspectives for future therapy I <i>Prof. Axel Dignaß (Agaplesion</i>
11:30 - 13:00	Poster Presentation & Lunch		Markus Krankenhaus)
13:00 - 13:45 13:00 - 13:15	Fraunhofer CIMD: Research Insights Part II Proximity inducing drugs for immune- mediated diseases PD Dr. Aimo Kannt (Fraunhofer ITMP)	16:35 - 16:55	Challenges for drug development for immune-mediated diseases I <i>Prof. Kay Tetzlaff (Boehringer Ingelheim)</i>
13:15 - 13:30	Alternatives for animal testing PD Dr. Katherina Sewald / Prof. Annette Bitsch	16:55 - 17:10	Summary and Perspectives <i>Board of Directors Fraunhofer CIMD</i>

4 Subject to changes